Athira Pharma is a biotechnology business based in the US. Athira Pharma shares (ATHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.65 – a decrease of 11.12% over the previous week. Athira Pharma employs 65 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.65 |
|---|---|
| 52-week range | $0.41 - $4.30 |
| 50-day moving average | $0.50 |
| 200-day moving average | $2.24 |
| Wall St. target price | $0.55 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6416 from 2024-11-18
| 1 week (2024-11-13) | -12.11% |
|---|---|
| 1 month (2024-10-18) | 35.79% |
| 3 months (2024-08-20) | -80.79% |
| 6 months (2024-05-20) | -74.54% |
| 1 year (2023-11-20) | -59.39% |
|---|---|
| 2 years (2022-11-18) | -80.07% |
| 3 years (2021-11-19) | 14.56 |
| 5 years (2019-11-17) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -47.53% |
| Return on equity TTM | -84.57% |
| Profit margin | 0% |
| Book value | $3.41 |
| Market Capitalization | $27.6 million |
TTM: trailing 12 months
We're not expecting Athira Pharma to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Athira Pharma's shares have ranged in value from as little as $0.4115 up to $4.2984. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athira Pharma's is 2.835. This would suggest that Athira Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Athira Pharma's beta into context you can compare it against those of similar companies.
Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.